there was a trend toward better odds of an excellent functional outcome -- survival without disability at 90 days -- among patients who received a single periprocedural intra-arterial injection of ...

The current study, conducted at 19 centers in China, evaluated the safety and effectiveness of injecting tenecteplase ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...

Intra-arterial injection. Premature infants. Risks from concomitant use with opioids; see Interactions. Monitor for respiratory depression and level of sedation; ensure availability of ...

Injecting tenecteplase into the artery after clot removal helps improve recovery in stroke survivors, leading to better ...

IV: 0.2mg given slowly over a period of no less than 60 seconds. Avoid intra-arterial, periarterial injection. Coronary artery disease or risk factors; may be more susceptible to developing MI and ...

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, ...